It seems that mds is something they could go after. But 92 days benefit? Pumpettees finally got some news. How will astex afford two ph3 trials? They have to figure out mds or aml? Second line is still all they are pointing at.
Why is there no evidence long term that it helps new MDS? The $1B market. Pumpettees maybe clueless on that question.
"only been treated recently". It would help if you had an undertanding of your drug. They are not getting patients early, because they know that it will not benefit like dacogen or vidaza. Something is missing? Granted they may have some benefit, but the key to sales is longer term benefit. Many cycles is sales. If dacogen only gave 90 days of benefits, you would not sell much. The other question here is how long would the patients have lived if they got no sgi-110?
In these releases, you have to look at what's not there. If you don't understand that, then you're in trouble.